Cara Therapeutics (NASDAQ:CARA – Get Rating) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday. CARA has been the subject of a number of other research reports. Piper Sandler decreased their target price on shares of Cara Therapeutics from $25.00 to $13.00 […]
Cara Therapeutics (NASDAQ:CARA – Get Rating) had its price target lowered by equities research analysts at HC Wainwright from $20.00 to $15.00 in a note issued to investors on Tuesday, The Fly reports. HC Wainwright’s price target would suggest a potential upside of 278.79% from the company’s current price. HC Wainwright also issued estimates for […]
Cara Therapeutics (NASDAQ:CARA – Get Rating) had its target price dropped by stock analysts at HC Wainwright from $20.00 to $15.00 in a report released on Tuesday, The Fly reports. HC Wainwright’s price target indicates a potential upside of 278.79% from the stock’s current price. HC Wainwright also issued estimates for Cara Therapeutics’ Q2 2023 […]
Shares of Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) have been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Rating) CEO Christopher Posner sold 3,869 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $4.40, for a total value of $17,023.60. Following the transaction, the chief executive officer now directly owns 172,514 shares in the company, […]